JP2009007285A - Hinokitiol-containing hydrophilic composition - Google Patents
Hinokitiol-containing hydrophilic composition Download PDFInfo
- Publication number
- JP2009007285A JP2009007285A JP2007169331A JP2007169331A JP2009007285A JP 2009007285 A JP2009007285 A JP 2009007285A JP 2007169331 A JP2007169331 A JP 2007169331A JP 2007169331 A JP2007169331 A JP 2007169331A JP 2009007285 A JP2009007285 A JP 2009007285A
- Authority
- JP
- Japan
- Prior art keywords
- hinokitiol
- composition
- weight
- viscosity
- glycerin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 title claims abstract description 190
- 239000000203 mixture Substances 0.000 title claims abstract description 104
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 229930007845 β-thujaplicin Natural products 0.000 title claims abstract description 95
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 63
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 56
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 21
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims abstract description 15
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims abstract description 7
- 210000000214 mouth Anatomy 0.000 claims abstract description 7
- 235000011187 glycerol Nutrition 0.000 claims description 30
- 238000003860 storage Methods 0.000 abstract description 8
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 235000019441 ethanol Nutrition 0.000 description 56
- 239000002674 ointment Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 16
- -1 maltitol fatty acid ester Chemical class 0.000 description 14
- 238000002156 mixing Methods 0.000 description 12
- 210000002200 mouth mucosa Anatomy 0.000 description 12
- 150000001298 alcohols Chemical class 0.000 description 10
- 239000002562 thickening agent Substances 0.000 description 10
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 239000000080 wetting agent Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 6
- 239000000194 fatty acid Substances 0.000 description 6
- 229930195729 fatty acid Natural products 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229960004063 propylene glycol Drugs 0.000 description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000000853 adhesive Substances 0.000 description 4
- 230000001070 adhesive effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000000551 dentifrice Substances 0.000 description 4
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000000057 synthetic resin Substances 0.000 description 4
- 229920003002 synthetic resin Polymers 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- MBDOYVRWFFCFHM-SNAWJCMRSA-N (2E)-hexenal Chemical compound CCC\C=C\C=O MBDOYVRWFFCFHM-SNAWJCMRSA-N 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010018276 Gingival bleeding Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004962 Polyamide-imide Substances 0.000 description 2
- 229910021536 Zeolite Inorganic materials 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000007718 adhesive strength test Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- ULDHMXUKGWMISQ-UHFFFAOYSA-N carvone Chemical compound CC(=C)C1CC=C(C)C(=O)C1 ULDHMXUKGWMISQ-UHFFFAOYSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004513 dentition Anatomy 0.000 description 2
- 239000003822 epoxy resin Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 208000011759 gum bleeding Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- CKFGINPQOCXMAZ-UHFFFAOYSA-N methanediol Chemical compound OCO CKFGINPQOCXMAZ-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 239000005011 phenolic resin Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920006122 polyamide resin Polymers 0.000 description 2
- 229920002312 polyamide-imide Polymers 0.000 description 2
- 229920001721 polyimide Polymers 0.000 description 2
- 239000009719 polyimide resin Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- YPFDHNVEDLHUCE-UHFFFAOYSA-N propane-1,3-diol Chemical compound OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 208000003265 stomatitis Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- 230000036346 tooth eruption Effects 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 239000010457 zeolite Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 1
- NFLGAXVYCFJBMK-RKDXNWHRSA-N (+)-isomenthone Natural products CC(C)[C@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-RKDXNWHRSA-N 0.000 description 1
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 description 1
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- XGRSAFKZAGGXJV-UHFFFAOYSA-N 3-azaniumyl-3-cyclohexylpropanoate Chemical compound OC(=O)CC(N)C1CCCCC1 XGRSAFKZAGGXJV-UHFFFAOYSA-N 0.000 description 1
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 1
- IJALWSVNUBBQRA-UHFFFAOYSA-N 4-Isopropyl-3-methylphenol Chemical compound CC(C)C1=CC=C(O)C=C1C IJALWSVNUBBQRA-UHFFFAOYSA-N 0.000 description 1
- AXCXHFKZHDEKTP-NSCUHMNNSA-N 4-methoxycinnamaldehyde Chemical compound COC1=CC=C(\C=C\C=O)C=C1 AXCXHFKZHDEKTP-NSCUHMNNSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical class C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 108010001682 Dextranase Proteins 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NFLGAXVYCFJBMK-UHFFFAOYSA-N Menthone Chemical compound CC(C)C1CCC(C)CC1=O NFLGAXVYCFJBMK-UHFFFAOYSA-N 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010037569 Purulent discharge Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 241000736892 Thujopsis dolabrata Species 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229910000323 aluminium silicate Inorganic materials 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 229940036350 bisabolol Drugs 0.000 description 1
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 1
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229930007050 cineol Natural products 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229940108928 copper Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- QGGZBXOADPVUPN-UHFFFAOYSA-N dihydrochalcone Chemical compound C=1C=CC=CC=1C(=O)CCC1=CC=CC=C1 QGGZBXOADPVUPN-UHFFFAOYSA-N 0.000 description 1
- PXLWOFBAEVGBOA-UHFFFAOYSA-N dihydrochalcone Natural products OC1C(O)C(O)C(CO)OC1C1=C(O)C=CC(C(=O)CC(O)C=2C=CC(O)=CC=2)=C1O PXLWOFBAEVGBOA-UHFFFAOYSA-N 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 229960005082 etohexadiol Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 229960002350 guaiazulen Drugs 0.000 description 1
- FWKQNCXZGNBPFD-UHFFFAOYSA-N guaiazulene Natural products CC(C)C1=CC=C(C)C2=CC=C(C)C2=C1 FWKQNCXZGNBPFD-UHFFFAOYSA-N 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000004021 humic acid Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- NFIDBGJMFKNGGQ-UHFFFAOYSA-N isopropylmethylphenol Natural products CC(C)CC1=CC=CC=C1O NFIDBGJMFKNGGQ-UHFFFAOYSA-N 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229930007503 menthone Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940074371 monofluorophosphate Drugs 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 229940042125 oral ointment Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 150000008379 phenol ethers Chemical class 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920005749 polyurethane resin Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 210000003456 pulmonary alveoli Anatomy 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- IMNMWKFKHDPTSB-UHFFFAOYSA-N silicic acid zirconium Chemical compound [Zr].[Si](O)(O)(O)O IMNMWKFKHDPTSB-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229960004711 sodium monofluorophosphate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 description 1
- 229960000401 tranexamic acid Drugs 0.000 description 1
- MBDOYVRWFFCFHM-UHFFFAOYSA-N trans-2-hexenal Natural products CCCC=CC=O MBDOYVRWFFCFHM-UHFFFAOYSA-N 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 229960003500 triclosan Drugs 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000004711 α-olefin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、ヒノキチオールを含有する親水性組成物に関し、特に、歯茎等の口腔粘膜に直接塗布することによってヒノキチオールの殺菌作用等を発揮させる口腔用軟膏剤として使用されるヒノキチオール含有親水性組成物に関する。 The present invention relates to a hydrophilic composition containing hinokitiol, and more particularly to a hinokitiol-containing hydrophilic composition used as an oral ointment that exerts a bactericidal action of hinokitiol by directly applying it to oral mucosa such as gums. .
ヒノキチオールは殺菌作用や組織収斂作用を有することが知られており、従来より、歯茎の出血、発赤、はれ、うみ、痛み、むずがゆさ、口のねばり、口臭などの、歯肉炎又は歯槽膿漏における諸症状の緩和や、口内炎の治療等を目的として軟膏剤や歯磨剤等の口腔用組成物に配合して使用されている。 Hinokitiol is known to have bactericidal and tissue astringent effects, and it has traditionally been known that gingivitis or alveoli, such as gum bleeding, redness, swelling, itchiness, pain, itching, mouth stickiness, bad breath, etc. It has been used in oral compositions such as ointments and dentifrices for the purpose of alleviating various symptoms of purulent discharge and treating stomatitis.
歯茎等の口腔粘膜用の軟膏剤として使用される口腔用組成物は、ヒノキチオールの殺菌作用や、使用感が優れていることから、油脂等の疎水性基剤を用いた疎水性の組成物としてよりも、親水性の物質を基剤とする親水性の組成物として構成するほうが好ましい。 The composition for oral cavity used as an ointment for oral mucosa such as gums is a hydrophobic composition using a hydrophobic base such as fats and oils because of its excellent bactericidal action and usability of hinokitiol. It is more preferable to configure as a hydrophilic composition based on a hydrophilic substance.
しかしながら親水性の条件においては、ヒノキチオールは極めて不安定であり、光、熱、樹脂、金属等に暴露することによって分解し、組成物中の含量が経時的に低下する傾向が強いことが知られている。この問題点を解決するため、特許文献1では、ヒノキチオール含有親水性ペースト状組成物に対してエチルアルコールを1重量%以上配合し、かつ容器として、特定の樹脂をコーティングし焼き付けたアルミニウムチューブを用いることが記載され、特許文献2では、ヒノキチオール含有液状口腔用組成物を、カーボンブラックの内層を有する多層プラスチックボトルに充填することが記載され、特許文献3では、ヒノキチオール配合剤にエデト酸二ナトリウム、ブチルヒドロキシアニソール、及びジブチルヒドロキシトルエンを配合することが記載され、特許文献4では、ヒノキチオールを含有する口腔用組成物に対して塩化ナトリウム等の水易溶性無機塩を配合することが記載されている。 However, under hydrophilic conditions, hinokitiol is extremely unstable and is known to decompose by exposure to light, heat, resin, metal, etc., and its content tends to decrease over time. ing. In order to solve this problem, Patent Document 1 uses an aluminum tube in which 1% by weight or more of ethyl alcohol is blended with a hinokitiol-containing hydrophilic paste-like composition, and a specific resin is coated and baked as a container. Patent Document 2 describes filling a hinokitiol-containing liquid oral composition in a multilayer plastic bottle having an inner layer of carbon black, and Patent Document 3 discloses edetate disodium as a hinokitiol compounding agent. It is described that butylhydroxyanisole and dibutylhydroxytoluene are blended, and Patent Document 4 describes that a water-soluble inorganic salt such as sodium chloride is blended with an oral composition containing hinokitiol. .
しかしながら、歯茎等の口腔粘膜用の軟膏剤として従来使用されている親水性組成物は乳白色のものであったが、これを歯茎等に塗布するとその塗布部分を第三者が容易に識別でき、外観上好ましいものではなかった。 However, the hydrophilic composition conventionally used as an ointment for oral mucosa such as gums was milky white, and when this was applied to gums etc., the application part could be easily identified by a third party, It was not preferable in appearance.
さらに、当該組成物は歯茎等の口腔粘膜に付着することによって治療効果を発現するものであるから、その粘着性の観点、及び塗布時の使用感の観点から、ある程度の粘性を有することが望まれるが、従来品が有する粘度は十分なレベルのものではなかった。
本発明は、上記現状に鑑み、歯茎等の口腔粘膜に直接塗布して使用するのに適したヒノキチオール含有親水性組成物であって、歯茎等への粘着性及び塗布時の使用感の観点から十分な粘度を保持しながらも、歯茎等への塗布後に目立ちにくいよう透明の外観を呈し、かつヒノキチオールの保存安定性にも優れているヒノキチオール含有親水性組成物を提供することを課題とする。 In view of the above situation, the present invention is a hinokitiol-containing hydrophilic composition suitable for direct application to the oral mucosa such as gums, from the viewpoint of adhesiveness to the gums and feeling during use. An object of the present invention is to provide a hinokitiol-containing hydrophilic composition that exhibits a transparent appearance so as to be inconspicuous after application to gums or the like while maintaining a sufficient viscosity, and that is also excellent in storage stability of hinokitiol.
本発明者らは、鋭意検討した結果、親水性組成物に配合する湿潤剤として最も一般的な多価アルコールであるグリセリンをヒノキチオール含有組成物に配合すると組成物が乳白色になるが、グリセリンに代えて2価のアルコールを配合すると、組成物が透明になること、及び組成物の粘度が格段に高くなることを見出した。さらには、2価のアルコールの配合量を増加させることによって、ヒノキチオールの保存安定性が著しく向上する(つまりは、ヒノキチオールの経時的な減少量が著しく少ない)ことを見出し、本発明を完成するに至った。 As a result of intensive investigations, the inventors have found that the composition becomes milky white when glycerin, which is the most common polyhydric alcohol blended in a hydrophilic composition, is blended with a hinokitiol-containing composition. It has been found that when a dihydric alcohol is added, the composition becomes transparent and the viscosity of the composition is remarkably increased. Furthermore, by increasing the blending amount of the dihydric alcohol, it was found that the storage stability of hinokitiol was remarkably improved (that is, the amount of hinokitiol decreased with time), and the present invention was completed. It came.
すなわち本発明は、ヒノキチオールを含有する親水性組成物であって、2価のアルコール類を組成物全量に対して30重量%以上含有し、かつグリセリンを含有していないことを特徴とするヒノキチオール含有親水性組成物に関する。 That is, the present invention is a hydrophilic composition containing hinokitiol, containing 30% by weight or more of divalent alcohols based on the total amount of the composition, and containing no glycerin. The present invention relates to a hydrophilic composition.
前記2価のアルコール類は、エチレングリコール、プロピレングリコール、及びブチレングリコールからなる群より選択される少なくとも1種であることが好ましい。 The divalent alcohol is preferably at least one selected from the group consisting of ethylene glycol, propylene glycol, and butylene glycol.
前記ヒノキチオール含有親水性組成物は、B型粘度計を用いて測定した粘度が10000cp以上であることが好ましい。 The hinokitiol-containing hydrophilic composition preferably has a viscosity of 10,000 cp or more measured using a B-type viscometer.
前記ヒノキチオールは含量が組成物全量に対して0.05重量%以上であることが好ましい。 The content of the hinokitiol is preferably 0.05% by weight or more based on the total amount of the composition.
前記ヒノキチオール含有親水性組成物は、口腔用組成物であることが好ましい。 The hinokitiol-containing hydrophilic composition is preferably an oral composition.
本発明のヒノキチオール含有親水性組成物は、十分な粘度を保持しながらも、歯茎等の口腔粘膜への塗布後に目立ちにくいよう透明の外観を呈するものであり、かつヒノキチオールの保存安定性にも優れているものである。 The hinokitiol-containing hydrophilic composition of the present invention exhibits a transparent appearance so as to be inconspicuous after application to the oral mucosa such as gums while maintaining a sufficient viscosity, and is excellent in storage stability of hinokitiol. It is what.
以下に本発明を詳細に説明する。 The present invention is described in detail below.
本発明のヒノキチオール含有組成物は、親水性の組成物であり、2価のアルコール類を組成物全量に対して30重量%以上含有し、かつグリセリンを含有しておらず、透明の外観を呈するものである。 The hinokitiol-containing composition of the present invention is a hydrophilic composition and contains 30% by weight or more of divalent alcohols with respect to the total amount of the composition, and does not contain glycerin and exhibits a transparent appearance. Is.
ここで親水性とは、本発明の組成物を、油脂等の疎水性基剤を用いた疎水性の組成物と区別することを意図しており、組成物の基剤が、2価のアルコールを含む親水性の物質からなるものを指す。特に、本発明の組成物は、2価のアルコールのほか、水を基剤とし、さらに増粘剤を配合することによってジェル状のものとして構成することが好ましい。 Here, the term “hydrophilic” is intended to distinguish the composition of the present invention from a hydrophobic composition using a hydrophobic base such as oil or fat, and the base of the composition is a divalent alcohol. The thing which consists of a hydrophilic substance containing. In particular, the composition of the present invention is preferably configured as a gel by mixing water with a base other than a dihydric alcohol and further adding a thickener.
本発明のヒノキチオール含有組成物の外観が透明であるとは、一般的な軟膏剤等が白色又は乳白色を呈しているのと区別することを意図しており、半透明も含まれる。外観が透明であると、本発明の組成物を歯茎等の口腔粘膜に塗布した後において、第三者がその塗布部分を一瞥により認識することは困難になるため好ましい。 The transparent appearance of the hinokitiol-containing composition of the present invention is intended to distinguish a general ointment or the like from white or milky white, and includes translucent. It is preferable that the appearance is transparent because it is difficult for a third party to recognize the applied portion at a glance after applying the composition of the present invention to the oral mucosa such as gums.
ヒノキチオールは7環構造を持つアルコール系の化合物であり、天然樹木精油の中で、青森ひば油の中に最も多く含まれている成分である。強い抗菌活性と広い抗菌スペクトルを有する、数少ない天然系殺菌剤のひとつである。本発明では天然のヒノキチオールを使用してもよいし、化学合成されたヒノキチオールを使用してもよい。簡便には、ヒノキチオールは、例えば、商品名「ヒノキチオール」として株式会社高砂ケミカルなどから商業的に入手可能である。 Hinokitiol is an alcoholic compound having a seven-ring structure, and is the most abundant component of natural tree essential oil in Aomori hiba oil. One of the few natural fungicides with strong antibacterial activity and broad antibacterial spectrum. In the present invention, natural hinokitiol may be used, or chemically synthesized hinokitiol may be used. For convenience, hinokitiol is commercially available from Takasago Chemical Co., Ltd. under the trade name “hinokitiol”, for example.
本発明の組成物におけるヒノキチオールの含量は特に限定されるものではなく、その用途や所望の治療効果に応じて適宜決定することができるが、通常、組成物全量に対して0.005〜1重量%である。好ましくは0.01重量%〜0.5重量%である。少なくすぎるとヒノキチオールの殺菌効果が十分に発揮されず、逆に多すぎると香味や安全性の点で問題が生じる可能性がある。一般に、組成物中のヒノキチオールの含量が増加すると、その経時的な減少率が増加していくので、ヒノキチオールの経時的分解の防止は、有効成分であるヒノキチオールの含量が高い組成物においてより困難になる。しかしながら、本発明の組成物にあっては、たとえヒノキチオールの含量を高くしても(具体的には組成物全量に対して0.05重量%以上、さらには0.1重量%以上であっても)、十分なレベルの保存安定性を達成することができる。 The content of hinokitiol in the composition of the present invention is not particularly limited and can be appropriately determined according to its use and desired therapeutic effect, but is usually 0.005 to 1 wt. %. Preferably it is 0.01 weight%-0.5 weight%. If the amount is too small, the sterilizing effect of hinokitiol will not be sufficiently exerted. Conversely, if the amount is too large, a problem may occur in terms of flavor and safety. In general, as the content of hinokitiol in the composition increases, the rate of decrease over time increases, so it is more difficult to prevent the degradation of hinokitiol over time in a composition with a high content of hinokitiol, the active ingredient. Become. However, in the composition of the present invention, even if the content of hinokitiol is high (specifically 0.05% by weight or more, further 0.1% by weight or more based on the total amount of the composition) Also) a sufficient level of storage stability can be achieved.
本発明の組成物はグリセリンを実質的に含有せず、2価のアルコール類を1種又は2種以上含有する。これによって、組成物が透明となるので口腔粘膜への塗布後の外観が良好であり、さらには組成物の粘度がグリセリン使用の場合と比較して高くなるので口腔粘膜への塗布に適した粘度に調整することが容易になり、治療効果を高めることができる。 The composition of the present invention contains substantially no glycerin and one or more divalent alcohols. This makes the composition transparent so that the appearance after application to the oral mucosa is good, and the viscosity of the composition is higher than when glycerin is used, so the viscosity is suitable for application to the oral mucosa. It is easy to make adjustments, and the therapeutic effect can be enhanced.
2価のアルコール類とは、アルコール性水酸基を1分子内に2個有する化合物であり、例えば、エチレングリコール、プロピレングリコール、トリメチレングリコール、1,2−ブチレングリコール、1,3−ブチレングリコール、テトラメチレングリコール、2,3−ブチレングリコール、ペンタメチレングリコール、2−ブテン−1,4−ジオール、ヘキシレングリコール、オクチレングリコール等が挙げられるが、本発明の効果の観点から、なかでも炭素数2〜6の2価アルコールが好ましく、特にエチレングリコール、プロピレングリコール、及びブチレングリコールからなる群より選択される少なくとも1種が好ましい。 Divalent alcohols are compounds having two alcoholic hydroxyl groups in one molecule, such as ethylene glycol, propylene glycol, trimethylene glycol, 1,2-butylene glycol, 1,3-butylene glycol, tetra Examples include methylene glycol, 2,3-butylene glycol, pentamethylene glycol, 2-butene-1,4-diol, hexylene glycol, octylene glycol, and the like. To 6 dihydric alcohols are preferred, and at least one selected from the group consisting of ethylene glycol, propylene glycol, and butylene glycol is particularly preferred.
本発明の組成物は2価のアルコールを組成物全量に対して30重量%以上含有するものである。グリセリンは、ヒノキチオールの安定性を向上させることが知られており、ヒノキチオール含有組成物にはグリセリンが頻繁に配合されているが、湿潤剤としてグリセリンを使用した場合には、組成物中のグリセリン含量が変化してもヒノキチオールの安定性はさほど変化しないが、湿潤剤を2価のアルコールとした場合には、その含量が増加するほどヒノキチオールの安定性が格段に向上していく傾向がある。このため、ヒノキチオールの安定性の観点から、2価アルコールの含量は40重量%以上としたほうが好ましく、50重量%以上としたほうがさらに好ましい。 The composition of the present invention contains a divalent alcohol in an amount of 30% by weight or more based on the total amount of the composition. Glycerin is known to improve the stability of hinokitiol, and glycerin is frequently included in hinokitiol-containing compositions, but when glycerin is used as a wetting agent, the glycerin content in the composition Although the stability of hinokitiol does not change so much even when the value of the humic acid changes, when the wetting agent is a dihydric alcohol, the stability of the hinokitiol tends to be remarkably improved as the content increases. For this reason, from the viewpoint of the stability of hinokitiol, the content of dihydric alcohol is preferably 40% by weight or more, and more preferably 50% by weight or more.
組成物中の含量が30重量%未満である場合、2価のアルコールであってもグリセリンであってもヒノキチオールの安定性は同程度であるが、30重量%以上になると、2価のアルコールはヒノキチオールの安定性を格段に向上させ、グリセリンのみを使用した場合には到達不可能な高レベルの安定性を達成することができる。しかし、2価アルコール類の含量を増やすことによる効果(例えば、合成樹脂焼付け金属容器におけるヒノキチオール残存率向上など)が現れにくくなるだけでなく、製剤が困難になったり、塗布時の使用感が悪化したりする傾向があるので、2価アルコール類の含量は80重量%以下が好ましく、70重量%以下がより好ましい。なお、当該2価アルコール類の含量とは、2価アルコールを2種以上配合する場合にはその合計含量を指す。 When the content in the composition is less than 30% by weight, the stability of hinokitiol is the same regardless of whether it is a dihydric alcohol or glycerin. The stability of hinokitiol is greatly improved, and a high level of stability that cannot be achieved when only glycerin is used can be achieved. However, not only is the effect of increasing the content of dihydric alcohols (for example, improving the residual ratio of hinokitiol in a synthetic resin baked metal container, etc.) difficult to formulate, and the feeling during use is deteriorated. The content of dihydric alcohols is preferably 80% by weight or less, more preferably 70% by weight or less. The content of the dihydric alcohol refers to the total content when two or more dihydric alcohols are blended.
組成物を透明とするため、グリセリンは本発明の組成物には実質的に配合されないものであるが、透明性が維持される範囲であれば、微量(例えば組成物全量に対して1重量%以下、0.5重量%以下、または0.1重量%以下)のグリセリンを配合することは可能である。ヒノキチオール含有組成物にグリセリンを一定量配合するとヒノキチオールが安定化することが知られているが、本発明の組成物では湿潤剤として2価アルコールを使用することによって、グリセリンを配合することなく、ヒノキチオールの十分な安定性を達成することができる。なお、グリセリンが配合されると組成物が乳白色を帯びるのは、ヒノキチオールが比較的親油性の高い化合物であることから、親水性が高いグリセリンへの溶解度が低いことが原因と考えられる。 In order to make the composition transparent, glycerin is not substantially blended in the composition of the present invention. However, if the transparency is maintained, a trace amount (for example, 1% by weight based on the total amount of the composition). Hereinafter, it is possible to mix | blend 0.5 weight% or less or 0.1 weight% or less glycerin. Although it is known that hinokitiol is stabilized when a certain amount of glycerin is blended in the hinokitiol-containing composition, the composition of the present invention uses a dihydric alcohol as a wetting agent, so that hinokitiol is blended without blending glycerin. Sufficient stability can be achieved. In addition, when glycerin is mix | blended, it is considered that the composition becomes milky white because hinokitiol is a compound having a relatively high lipophilicity, and thus has low solubility in glycerin having high hydrophilicity.
また、ヒノキチオール含有組成物に低級アルコール(エチルアルコール、プロピルアルコール、ブチルアルコール(好ましくは、エチルアルコール)など)を一定量配合するとヒノキチオールが安定化することが知られている。本発明の組成物に対して低級アルコールを配合してもよいが、本発明の組成物は、例えばエチルアルコールを含有していない場合にあっても、ヒノキチオールの十分な安定性を達成することができる。例えば、エチルアルコールは歯茎に塗布すると刺激を誘発するものであるから、本発明の組成物が歯茎等への塗布用である場合には、低級アルコールを配合しないほうが好ましいが、ヒノキチオールの安定性を考慮するのであれば、低級アルコールを組成物全量に対して1重量%以上、好ましくは1〜50重量%、より好ましくは1〜30重量%、さらに好ましくは1〜10重量%配合することもできる。また、低級アルコールによる刺激性を考慮するのであれば、配合量は微量(例えば組成物全量に対して1重量%未満、0.5重量%未満、または0.1重量%未満)であることが好ましい。 It is also known that hinokitiol is stabilized when a certain amount of lower alcohol (ethyl alcohol, propyl alcohol, butyl alcohol (preferably ethyl alcohol)) is blended with the hinokitiol-containing composition. Although a lower alcohol may be blended with the composition of the present invention, the composition of the present invention can achieve sufficient stability of hinokitiol even when it does not contain ethyl alcohol, for example. it can. For example, since ethyl alcohol induces irritation when applied to gums, when the composition of the present invention is for application to gums or the like, it is preferable not to add lower alcohol, but the stability of hinokitiol is improved. In consideration, the lower alcohol may be blended in an amount of 1% by weight or more, preferably 1 to 50% by weight, more preferably 1 to 30% by weight, and still more preferably 1 to 10% by weight based on the total amount of the composition. . If the irritation due to the lower alcohol is taken into consideration, the blending amount is very small (for example, less than 1% by weight, less than 0.5% by weight, or less than 0.1% by weight based on the total amount of the composition). preferable.
本発明の組成物は通常、2価アルコールとともに、水を基剤として含有するものである。水の配合量は、2価アルコールの配合量に応じて適宜決定すればよいが、2価アルコールと水の合計量が組成物全量に対して、およそ80〜95重量%程度を占めるようにすることが好ましい。 The composition of the present invention usually contains water as a base together with a dihydric alcohol. The blending amount of water may be appropriately determined according to the blending amount of the dihydric alcohol, but the total amount of the dihydric alcohol and water accounts for about 80 to 95% by weight with respect to the total amount of the composition. It is preferable.
本発明の組成物の粘度は特に限定されないが、B型粘度計(例えば、B型粘度計ヘリパススタンド付(BrookField社製DV−II+)、ヘリパススピンドルセット(typeC=93))を用いて測定した粘度が5000cp以上を示すことが好ましく、8000cp以上を示すことがより好ましく、10000cp以上を示すことがさらに好ましく、12000cp以上を示すことが特に好ましく、15000cp以上を示すことが最も好ましい。この範囲では、口腔粘膜に塗布する際の使用感が良好となり、また、口腔粘膜等への組成物の粘着性が向上することによってヒノキチオールに由来する治療効果を高めることができる。また、2価アルコールの種類及び配合量が同一である場合には、組成物の粘度が高くなるほど、ヒノキチオールの安定性が向上する傾向があるので、この観点からも好ましい。しかしながら、粘度を高くすることによる効果(例えば、合成樹脂焼付け金属容器におけるヒノキチオール残存率向上など)が現れにくくなるだけでなく、製剤が困難になったり、塗布時の使用感が悪化したりする傾向があるので、50000cp以下程度の粘度に調製することが好ましい。本発明の組成物の粘度は、主に、組成物に配合する増粘剤の種類及び配合量を適宜変更することによって容易に調整可能である。 The viscosity of the composition of the present invention is not particularly limited, but using a B-type viscometer (for example, a B-type viscometer with a helipath stand (DV-II + manufactured by BrookField), a helipath spindle set (type C = 93)). The measured viscosity is preferably 5000 cp or more, more preferably 8000 cp or more, further preferably 10,000 cp or more, particularly preferably 12000 cp or more, and most preferably 15000 cp or more. In this range, the usability when applied to the oral mucosa is improved, and the therapeutic effect derived from hinokitiol can be enhanced by improving the adhesiveness of the composition to the oral mucosa. Moreover, when the kind and compounding quantity of a bihydric alcohol are the same, since there exists a tendency for the stability of hinokitiol to improve, so that the viscosity of a composition becomes high, it is preferable also from this viewpoint. However, not only the effects of increasing the viscosity (for example, the improvement of the remaining ratio of hinokitiol in a synthetic resin-baked metal container) are difficult to appear, but the formulation tends to be difficult and the feeling of use during application tends to deteriorate. Therefore, it is preferable to adjust the viscosity to about 50,000 cp or less. The viscosity of the composition of the present invention can be easily adjusted mainly by appropriately changing the type and blending amount of the thickener to be blended in the composition.
増粘剤としては特に限定されないが、例えば、カラギーナン(ι、λ、κ)、アルギン酸、アルギン酸ナトリウム、アルギン酸プロピレングリコールエステル、カルシウム含有アルギン酸ナトリウム、アルギン酸カリウム、アルギン酸カルシウム、アルギン酸アンモニウム等のアルギン酸塩及びその誘導体、キサンタンガム、グアーガム、ゼラチン、寒天、カルボキシメチルセルロースナトリウム、ヒドロキシプロピルメチルセルロース、ヒドロキシエチルセルロース、ポリアクリル酸ナトリウム、カルボキシビニルポリマー等が挙げられる。これらのうち1種類のみを使用してもよいし、2種類以上を使用してもよい。なかでも、カルボキシメチルセルロースナトリウムおよびヒドロキシプロピルメチルセルロースが好ましい。増粘剤として、カルボキシメチルセルロースナトリウムとヒドロキシプロピルメチルセルロースを併用する場合、カルボキシメチルセルロースナトリウムの2%粘度(25℃)は500cp以下であることが好ましく、5〜300cpであることがより好ましく、5〜200cpであることがさらに好ましく、5〜100cpがとくに好ましく、5〜50cpがもっとも好ましい。ヒドロキシプロピルメチルセルロースの2%粘度(25℃)については1000〜6000cpであることが好ましく、2000〜5000cpであることがより好ましく、3000〜5000cpがさらに好ましい。この範囲内であれば、水分が多い環境、例えば口腔用の組成物として、粘度だけではなく、粘着強さにおいてもとくに優れた組成物とすることができる。 The thickener is not particularly limited, and examples thereof include carrageenan (ι, λ, κ), alginic acid, sodium alginate, propylene glycol ester alginate, calcium-containing sodium alginate, potassium alginate, calcium alginate, ammonium alginate, and the like. Derivatives, xanthan gum, guar gum, gelatin, agar, sodium carboxymethylcellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose, sodium polyacrylate, carboxyvinyl polymer and the like. Of these, only one type may be used, or two or more types may be used. Of these, sodium carboxymethylcellulose and hydroxypropylmethylcellulose are preferred. When sodium carboxymethyl cellulose and hydroxypropyl methyl cellulose are used in combination as a thickener, the 2% viscosity (25 ° C.) of sodium carboxymethyl cellulose is preferably 500 cp or less, more preferably 5 to 300 cp, and more preferably 5 to 200 cp. Is more preferable, 5 to 100 cp is particularly preferable, and 5 to 50 cp is most preferable. The 2% viscosity (25 ° C.) of hydroxypropylmethylcellulose is preferably 1000 to 6000 cp, more preferably 2000 to 5000 cp, and still more preferably 3000 to 5000 cp. If it exists in this range, it can be set as the composition which was excellent especially not only in the viscosity but also in the adhesive strength as a composition with much moisture, for example, oral cavity.
また、増粘剤の配合量としては、特に限定されず、本発明の組成物が所望の粘度となるように適宜調整すればよいが、通常、0.1〜10重量%程度である。 Further, the amount of the thickener is not particularly limited, and may be appropriately adjusted so that the composition of the present invention has a desired viscosity, but is usually about 0.1 to 10% by weight.
本発明の組成物には上記成分のほか、その目的や種類等に応じて、必要により以下の成分を通常の使用量の範囲内で配合することができる。 In addition to the above-described components, the following components can be blended in the composition of the present invention within the range of the usual amount of use, if necessary, depending on the purpose and type.
<界面活性剤>ラウリル硫酸ナトリウム、ラウロイルサルコシンナトリウム、アルキルスルホコハク酸ナトリウム、ヤシ油脂肪酸モノグリセリンスルホン酸ナトリウム、α−オレフィンスルホン酸ナトリウム、N−アシルグルタメート等のN−アシルアミノ酸塩、2−アルキル−N−カルボキシメチル−N−ヒドロキシエチルイミダゾリニウムベタイン、マルチトール脂肪酸エステル、ショ糖脂肪酸エステル、ポリグリセリン脂肪酸エステル、脂肪酸ジエタノールアミド、ポリオキシエチレンソルビタンモノステアレート、ポリオキシエチレンソルビタンモノオレエート、ポリオキシエチレン硬化ヒマシ油、ポリオキシエチレン脂肪酸エステル等。 <Surfactant> Sodium lauryl sulfate, sodium lauroyl sarcosine, sodium alkyl sulfosuccinate, sodium coconut oil fatty acid monoglycerol sulfonate, sodium α-olefin sulfonate, N-acyl glutamate, N-acyl amino acid salts, 2-alkyl- N-carboxymethyl-N-hydroxyethylimidazolinium betaine, maltitol fatty acid ester, sucrose fatty acid ester, polyglycerin fatty acid ester, fatty acid diethanolamide, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, poly Oxyethylene hydrogenated castor oil, polyoxyethylene fatty acid ester, etc.
<甘味剤>サッカリンナトリウム、アセスルファムカリウム、ソルビトール、キシリトール、エリスリトール、アスパルテーム、トレハロース、ステビオサイド、ステビアエキス、パラメトキシシンナミックアルデヒド、ネオヘスペリジルジヒドロカルコン、ペリラルチン等。 <Sweeting agent> Saccharin sodium, acesulfame potassium, sorbitol, xylitol, erythritol, aspartame, trehalose, stevioside, stevia extract, paramethoxycinnamic aldehyde, neohesperidyl dihydrochalcone, perilartine and the like.
<防腐剤>メチルパラベン、エチルパラベン、プロピルパラベン、ブチルパラベン等のパラベン類、安息香酸ナトリウム、フェノキシエタノール、塩酸アルキルジアミノエチルグリシン等。 <Preservative> Parabens such as methylparaben, ethylparaben, propylparaben, butylparaben, sodium benzoate, phenoxyethanol, alkyldiaminoethylglycine hydrochloride and the like.
<香料成分>l−メントール、アネトール、メントン、シネオール、リモネン、カルボン、メチルサリシレート、エチルブチレート、オイゲノール、チモール、シンナミックアルデヒド、トランス−2−ヘキセナール等。これらの成分は単品で配合してもよいが、これらを含有する精油等として配合してもよい。また、上記香料成分に加え、脂肪族アルコールやそのエステル、テルペン系炭化水素、フェノールエーテル、アルデヒド、ケトン、ラクトン等の香料成分、精油を配合してもよい。 <Perfume ingredients> l-menthol, anethole, menthone, cineol, limonene, carvone, methyl salicylate, ethyl butyrate, eugenol, thymol, cinnamic aldehyde, trans-2-hexenal and the like. These components may be blended alone, but may be blended as an essential oil containing these components. In addition to the above fragrance components, fragrance components such as aliphatic alcohols and esters thereof, terpene hydrocarbons, phenol ethers, aldehydes, ketones, and lactones, and essential oils may be blended.
<ヒノキチオール以外の有効成分>アラントイン、パンテノール、塩化リゾチーム、モノフルオロホスフェート、フッ化ナトリウム、フッ化カリウム、モノフルオロリン酸ナトリウム、ポリエチレングリコール、ポリビニルピロリドン、ゼオライト、アスコルビン酸、クロルヘキシジン塩類、塩化セチルピリジニウム、塩化ベンザルコニウム、塩化ベンゼトニウム、ビサボロール、トリクロサン、イソプロピルメチルフェノール、酢酸トコフェロール、ε−アミノカプロン酸、トラネキサム酸、ジヒドロコレステロール、グリチルレチン酸、グリチルリチン酸塩類、銅クロロフィリン塩、塩化ナトリウム、グァイアズレンスルホン酸塩、デキストラナーゼ、塩酸ピリドキシン等。 <Active ingredients other than hinokitiol> Allantoin, panthenol, lysozyme chloride, monofluorophosphate, sodium fluoride, potassium fluoride, sodium monofluorophosphate, polyethylene glycol, polyvinylpyrrolidone, zeolite, ascorbic acid, chlorhexidine salts, cetylpyridinium chloride Benzalkonium chloride, benzethonium chloride, bisabolol, triclosan, isopropylmethylphenol, tocopherol acetate, ε-aminocaproic acid, tranexamic acid, dihydrocholesterol, glycyrrhetinic acid, glycyrrhizinate, copper chlorophyllin salt, sodium chloride, guaiazulene sulfonic acid Salt, dextranase, pyridoxine hydrochloride, etc.
<研磨剤>
沈降性シリカ、シリカゲル、アルミノシリケート、ジルコノシリケート、第2リン酸カルシウム2水和物及び無水和物、ピロリン酸カルシウム、炭酸カルシウム、水酸化アルミニウム、アルミナ、炭酸マグネシウム、第3リン酸マグネシウム、ゼオライト、ケイ酸ジルコニウム、合成樹脂系研磨剤等。
<Abrasive>
Precipitated silica, silica gel, aluminosilicate, zirconosilicate, dibasic calcium phosphate dihydrate and anhydrous, calcium pyrophosphate, calcium carbonate, aluminum hydroxide, alumina, magnesium carbonate, tribasic magnesium phosphate, zeolite, silicic acid Zirconium, synthetic resin abrasive, etc.
<その他>青色1号等の色素、酸化チタン等の顔料、ジブチルヒドロキシトルエン等の酸化防止剤、チャ乾留液、グルタミン酸ナトリウム等の矯味剤等。 <Others> Pigments such as Blue No. 1, pigments such as titanium oxide, antioxidants such as dibutylhydroxytoluene, tea dry distillation liquid, and flavoring agents such as sodium glutamate.
本発明のヒノキチオール含有親水性組成物は口腔用組成物として用いることが好ましい。ここでいう口腔用組成物としては、歯茎の出血、発赤、はれ、うみ、痛み、むずがゆさ、口のねばり、口臭などの、歯肉炎又は歯槽膿漏における諸症状の緩和や、歯肉炎、歯槽膿漏、齲蝕、口内炎等の口腔内疾患の予防、治療を目的とした組成物をいい、剤型としては、練歯磨剤、液状歯磨剤、液体歯磨剤等の歯磨剤、軟膏剤、液剤、パスタ剤等が挙げられるが、特に、歯茎等の口腔粘膜に直接塗布することを意図した軟膏剤、なかでも透明性に優れたジェル型の軟膏剤として最も好適に使用することができる。 The hinokitiol-containing hydrophilic composition of the present invention is preferably used as an oral composition. The composition for oral cavity used herein includes alleviation of various symptoms in gingivitis or alveolar abscess, such as gum bleeding, redness, swelling, itch, pain, itching, mouth stickiness, bad breath, etc. A composition intended for the prevention and treatment of oral diseases such as inflammation, alveolar pyorrhea, dental caries and stomatitis. The dosage form includes toothpaste, liquid dentifrice, liquid dentifrice and other dentifrices and ointments. , Liquids, pasta agents, etc., but can be most suitably used especially as an ointment intended to be applied directly to the oral mucosa such as gums, especially a gel-type ointment with excellent transparency. .
本発明の組成物は、各種成分を混合、攪拌することによって製造することができるが、その製法は特に限定されない。 Although the composition of this invention can be manufactured by mixing and stirring various components, the manufacturing method is not specifically limited.
当該組成物を充填する容器としては特に限定されず、チューブ、ボトル等どのような形態のものであってもよい。容器の材質としても特に限定されず、例えば、アルミニウム等の金属、ガラス、ポリエチレンテレフタレート、ポリエチレン、ポリプロピレン等のプラスチックが挙げられる。ヒノキチオールは光への暴露によって分解が促進されるので、透光性のガラスやプラスチック等を使用する場合には、外面を非透光性のフィルム等で覆うことにより遮光をすることが好ましい。また、金属を使用する場合には、ヒノキチオールと金属との接触を回避するため、金属の内面を各種合成樹脂でコーティングし焼き付けたものを使用することが好ましい。合成樹脂としては特に限定されず、例えば、ポリアミドイミド樹脂、ポリアミド樹脂、ポリイミド樹脂、エポキシ・フェノール樹脂、エポキシ樹脂、フェノール樹脂、ポリウレタン樹脂等が挙げられるが、組成物中にエチルアルコールなどの低級アルコールを配合する場合には、ヒノキチオールの安定性の点からポリアミド樹脂、ポリイミド樹脂またはポリアミドイミド樹脂が好ましい。 The container for filling the composition is not particularly limited, and may be in any form such as a tube or a bottle. The material of the container is not particularly limited, and examples thereof include metals such as aluminum, plastics such as glass, polyethylene terephthalate, polyethylene, and polypropylene. Since degradation of hinokitiol is accelerated by exposure to light, when using translucent glass or plastic, it is preferable to shield the outer surface by covering it with a non-translucent film or the like. Moreover, when using a metal, in order to avoid contact with a hinokitiol and a metal, it is preferable to use what baked the inner surface of the metal coated with various synthetic resins. The synthetic resin is not particularly limited, and examples thereof include polyamideimide resin, polyamide resin, polyimide resin, epoxy / phenol resin, epoxy resin, phenol resin, polyurethane resin, etc., but lower alcohol such as ethyl alcohol in the composition. Is preferably a polyamide resin, a polyimide resin or a polyamideimide resin from the viewpoint of the stability of hinokitiol.
以下に実施例を掲げて本発明を詳細に説明するが、本発明はこれら実施例に限定されるものではない。なお、各評価及び測定は下記のようにして行った。
(1)透明性
調製した各軟膏剤を目視により観察し、透明と判断できたものを「○」と評価し、透明とは判断できず乳白色又は白色を呈しているものを「×」と評価した。
(2)粘度
粘度を測定する機器としては、B型粘度計ヘリパススタンド付(BrookField社製DV−II+)、及びヘリパススピンドルセット(typeC=93)を使用した。粘度の測定手順は以下のようにした。
1)調製した各軟膏剤65gを、M−70ビン(柏洋硝子株式会社製)に空気が入らないように充填し、フタをする。25℃に1時間以上置いて自然に空気を抜く。
2)ヘリパススピンドルtypeCをセットしたDV−II+をスピンドルが試料の中央に来るよう沈める(スピンドル回転数は100rpm)。
3)スピンドルを回転・ヘリパススタンドを上下運動させる。この時、ヘリパススタンドの最上点は試料からスピンドルが出ない範囲、最下点はM−70ビン(柏洋硝子株式会社製)の下面にスピンドルが接触しない高さとする。トルク%が最大となるよう調整した後、粘度表示に切り替え、粘度を測定する。
(3)ヒノキチオール残存量
調製した各軟膏剤を、表2〜4に示した各容器に、空気が入らないように充填した後、50℃、60%RHの条件下で1カ月間保存をした。各軟膏剤中のヒノキチオールについて保存前後で液体クロマトグラフィーにより定量試験を行った。各軟膏剤についてヒノキチオールの残存率を下記式より算出した。
残存率(%)=[(上記保存後のヒノキチオール含量)/(軟膏剤調製時のヒノキチオール含量)]/100
表2〜4で示したヒノキチオール残存量は、表4中の比較例13の場合について得られた上記の残存率を100.0%として、各実施例及び比較例の残存率を相対比(%)で示した。なお各表中の「平均値」とは、各容器について得られた残存量を相加平均して算出した数値である。
比較例1〜12
表1に示す組成(単位:重量%)に従い、以下に示す方法により調製したヒノキチオール溶液、増粘剤分散液およびグリチルリチン酸二カリウム溶液を真空攪拌装置(型式 PVQ−5(3)UN(みづほ工業株式会社製))により一定時間混錬脱泡させることによって、歯茎に対して指で直接塗布して使用することを目的としたペースト状の歯槽膿漏治療用軟膏剤を製し、その透明性を評価した。結果を表1に示す。
(ヒノキチオール溶液)
ヒノキチオールを、薄荷油、香料、2価アルコールの一部およびモノオレイン酸ポリオキシエチレンソルビタンに溶解させて、ヒノキチオール溶液を調製した。
(増粘剤分散液)
増粘剤(カルボキシメチルセルロースナトリウムおよびヒドロキシプロピルメチルセルロース)を、残部の2価アルコールに分散させた増粘剤分散液を調製した。
(グリチルリチン酸二カリウム溶液)
グリチルリチン酸二カリウムおよびグリセリンを精製水に溶解させたグリチルリチン酸二カリウム溶液を調製した。
EXAMPLES The present invention will be described in detail below with reference to examples, but the present invention is not limited to these examples. Each evaluation and measurement was performed as follows.
(1) Transparency Observe each prepared ointment by visual observation, evaluate that it was judged to be transparent as "○", and evaluate that it was milky white or white that could not be judged as transparent as "X" did.
(2) Viscosity As an instrument for measuring the viscosity, a B-type viscometer with a helipath stand (DV-II + manufactured by BrookField) and a helicopter spindle set (type C = 93) were used. The procedure for measuring the viscosity was as follows.
1) Each prepared ointment 65g is filled so that air may not enter M-70 bottles (manufactured by Koyo Glass Co., Ltd.) and covered. Leave at 25 ° C for 1 hour or longer to deflate naturally.
2) Sink the DV-II + with the helipath spindle type C set so that the spindle comes to the center of the sample (spindle speed is 100 rpm).
3) Rotate the spindle and move the helicopt stand up and down. At this time, the uppermost point of the helipath stand is a range where the spindle does not come out from the sample, and the lowermost point is a height at which the spindle does not contact the lower surface of the M-70 bin (manufactured by Koyo Glass Co., Ltd.). After adjusting the torque% to the maximum, switch to the viscosity display and measure the viscosity.
(3) Remaining amount of hinokitiol Each ointment prepared was filled in each container shown in Tables 2 to 4 so as not to enter air, and then stored for 1 month under conditions of 50 ° C. and 60% RH. . The hinokitiol in each ointment was quantitatively tested by liquid chromatography before and after storage. The residual ratio of hinokitiol was calculated from the following formula for each ointment.
Residual rate (%) = [(hinokitiol content after storage) / (hinokitiol content during preparation of ointment)] / 100
The remaining amounts of hinokitiol shown in Tables 2 to 4 are the relative ratios (%) of the residual ratios of the examples and comparative examples, with the residual ratio obtained in the case of Comparative Example 13 in Table 4 being 100.0%. ). The “average value” in each table is a numerical value calculated by arithmetically averaging the residual amount obtained for each container.
Comparative Examples 1-12
According to the composition (unit: wt%) shown in Table 1, the hinokitiol solution, thickener dispersion and dipotassium glycyrrhizinate solution prepared by the following method were mixed in a vacuum stirrer (model PVQ-5 (3) UN (Mizuho Industry Co., Ltd.). Made by the company))) for a certain period of time to produce a paste-like ointment for the treatment of alveolar pyorrhea intended to be applied directly to the gums with a finger and used for transparency Evaluated. The results are shown in Table 1.
(Hinokitiol solution)
Hinokitiol solution was prepared by dissolving hinokitiol in light-weight oil, fragrance, part of dihydric alcohol and polyoxyethylene sorbitan monooleate.
(Thickener dispersion)
A thickener dispersion in which thickeners (sodium carboxymethylcellulose and hydroxypropylmethylcellulose) were dispersed in the remaining dihydric alcohol was prepared.
(Dipotassium glycyrrhizinate solution)
A dipotassium glycyrrhizinate solution in which dipotassium glycyrrhizinate and glycerin were dissolved in purified water was prepared.
実施例1〜21及び比較例13〜24
同様に、歯茎への直接塗布による使用を目的としたペースト状の歯槽膿漏治療用軟膏剤を、表2〜4に示す組成(単位:重量%)に従い、比較例1と同様に調製し、その透明性、粘度、及びヒノキチオール残存量を評価、測定した。結果を表2〜4に示す。
Examples 1-21 and Comparative Examples 13-24
Similarly, a paste-like alveolus treatment ointment intended for use by direct application to the gums was prepared in the same manner as in Comparative Example 1 according to the composition shown in Tables 2 to 4 (unit:% by weight). The transparency, viscosity, and residual amount of hinokitiol were evaluated and measured. The results are shown in Tables 2-4.
2価アルコールを30重量%以上含有しグリセリンを含有しない実施例1〜21は、2価アルコールの含有量が20重量%以下である比較例14〜22や、グリセリンを使用した比較例13、23および24と比較してヒノキチオールの残存量がはるかに多く、ヒノキチオールの保存安定性の点で格段に優れていることが分かる。 Examples 1-21 containing 30% by weight or more of dihydric alcohol and not containing glycerin are Comparative Examples 14-22, in which the content of dihydric alcohol is 20% by weight or less, and Comparative Examples 13, 23 using glycerin. It can be seen that the remaining amount of hinokitiol is much larger than those of No. 24 and No. 24, and that the storage stability of hinokitiol is much superior.
グリセリンを配合した比較例13、23および24ではグリセリンの含量が増加してもヒノキチオールの残存量はさほど変化しておらず、配合量の増加によってヒノキチオールの安定性が著しく向上する(例えば実施例1、4、7、及び比較例14、17)のは2価アルコールに特有の現象であることが分かる。 In Comparative Examples 13, 23 and 24 in which glycerin was blended, the remaining amount of hinokitiol did not change much even when the glycerin content was increased, and the stability of hinokitiol was significantly improved by increasing the blending amount (for example, Example 1). 4 and 7 and Comparative Examples 14 and 17) are characteristic of dihydric alcohols.
比較例20〜22と比較例23との比較から、配合量が20重量%程度であると2価アルコールの場合のヒノキチオールの安定性と、グリセリンの場合のそれとは同程度である(むしろ、グリセリンのほうが良好である)。しかし、配合量が30重量%以上になると、2価アルコールはヒノキチオールの安定性を格段に向上させ、グリセリンを使用した場合には到達し得ない高水準のヒノキチオール安定性を達成することができる。 From comparison between Comparative Examples 20 to 22 and Comparative Example 23, when the blending amount is about 20% by weight, the stability of hinokitiol in the case of dihydric alcohol is almost the same as that in the case of glycerin (rather than glycerin). Is better). However, when the blending amount is 30% by weight or more, the dihydric alcohol significantly improves the stability of hinokitiol, and can achieve a high level of hinokitiol stability that cannot be achieved when glycerin is used.
また、例えば実施例7〜9と実施例17〜19との対比、あるいは実施例8及び13〜16の比較から、2価アルコールの種類及び配合量が同一である場合には、軟膏剤の粘度が高くなるほど、ヒノキチオールの安定性が増加する傾向にあることが分かる。 In addition, for example, when the types and blending amounts of the dihydric alcohol are the same from the comparison between Examples 7 to 9 and Examples 17 to 19 or the comparison between Examples 8 and 13 to 16, the viscosity of the ointment It turns out that there exists a tendency for the stability of hinokitiol to increase, so that becomes high.
しかしながら、例えば実施例17〜19と、比較例14〜16とを比較すると、増粘剤の配合量が少ないために実施例17〜19の粘度は比較例14〜16の粘度の2分の1以下であるにも関わらず、ヒノキチオール安定性は実施例17〜19のほうが良好である。これは実施例17〜19では2価アルコール含量がより高いためと考えられる。このことより、ヒノキチオールの安定性には、軟膏剤の粘度の高さだけでなく、2価アルコールが30重量%以上含有されていることが重要であることが分かる。比較例13、23および24は、湿潤剤がグリセリンである場合には軟膏剤の粘度が極めて低いことが分かる。 However, for example, when Examples 17 to 19 and Comparative Examples 14 to 16 are compared, the viscosity of Examples 17 to 19 is half that of Comparative Examples 14 to 16 because the amount of the thickener is small. In spite of the following, the hinokitiol stability is better in Examples 17-19. This is considered to be because the dihydric alcohol content is higher in Examples 17-19. From this, it is understood that not only the viscosity of the ointment is high but also that 30% by weight or more of dihydric alcohol is contained in the stability of hinokitiol. Comparative Examples 13, 23 and 24 show that the viscosity of the ointment is very low when the wetting agent is glycerin.
さらに、例えば、エチルアルコール10.0重量%をさらに含有させた以外は実施例8と同様に調製した処方の場合、ヒノキチオール残存率の相対比(平均)が123.9%であり、2価アルコールのみを含有している場合とほぼ同様の結果であり、2価アルコールを配合しておけば、エチルアルコールなどの低級アルコールと併用しても良好なヒノキチオール安定性を達成することができることが分かった。また、プロピレングリコールの含量を25重量%とし、さらにブチレングリコールを25重量%含有させた以外は実施例8と同様に調製した処方の場合(2価アルコールを併用)、ヒノキチオール残存率の相対比(平均)が122.5%であり、2価アルコールを単独で使用した場合と同様の結果であった。 Further, for example, in the case of the formulation prepared in the same manner as in Example 8 except that 10.0% by weight of ethyl alcohol was further added, the relative ratio (average) of the remaining ratio of hinokitiol was 123.9%, and the dihydric alcohol The results are almost the same as the case of containing only dihydric alcohol, and it was found that if dihydric alcohol was added, good hinokitiol stability could be achieved even in combination with lower alcohols such as ethyl alcohol. . Further, in the case of the formulation prepared in the same manner as in Example 8 except that the content of propylene glycol was 25% by weight and further 25% by weight of butylene glycol (in combination with dihydric alcohol), the relative ratio of hinokitiol residual ratio ( The average) was 122.5%, which was the same result as when dihydric alcohol was used alone.
処方例1〜65
表5〜12に記載の処方に従い、定法により各種組成物を調製した。
Formulation Examples 1 to 65
Various compositions were prepared by conventional methods according to the formulations described in Tables 5-12.
*1) JIS T 6525−1「義歯床安定用こ(糊)材−第1部:粘着型義歯床安定用こ(糊)材」に記載の「6.5粘着強さ試験I」の測定方法に従って測定した。
*2) JIS T 6525−1「義歯床安定用こ(糊)材−第1部:粘着型義歯床安定用こ(糊)材」に記載の「6.5粘着強さ試験II」の測定方法に従って測定した。
* 1) Measurement of “6.5 Adhesive Strength Test I” described in JIS T 6525-1, “Dentition Base Stabilizer (Glue) Material—Part 1: Adhesive Denture Base Stabilizer Material (Glue)” Measured according to the method.
* 2) Measurement of “6.5 Adhesive Strength Test II” described in JIS T 6525-1, “Dentition Base Stabilizer (Glue)-Part 1: Adhesive Denture Base Stabilizer (Glue)” Measured according to the method.
Claims (5)
2価のアルコール類を組成物全量に対して30重量%以上含有し、かつ
グリセリンを含有していないことを特徴とするヒノキチオール含有親水性組成物。 A hydrophilic composition containing hinokitiol,
A hinokitiol-containing hydrophilic composition comprising 30% by weight or more of a divalent alcohol based on the total amount of the composition and containing no glycerin.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007169331A JP5274792B2 (en) | 2007-06-27 | 2007-06-27 | Hinokitiol-containing hydrophilic composition |
PCT/JP2008/061764 WO2009001937A1 (en) | 2007-06-27 | 2008-06-27 | Hydrophilic composition containing hinokitiol |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007169331A JP5274792B2 (en) | 2007-06-27 | 2007-06-27 | Hinokitiol-containing hydrophilic composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009007285A true JP2009007285A (en) | 2009-01-15 |
JP5274792B2 JP5274792B2 (en) | 2013-08-28 |
Family
ID=40185746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007169331A Active JP5274792B2 (en) | 2007-06-27 | 2007-06-27 | Hinokitiol-containing hydrophilic composition |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP5274792B2 (en) |
WO (1) | WO2009001937A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019069927A (en) * | 2017-10-11 | 2019-05-09 | 小林製薬株式会社 | Oral composition |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS491718A (en) * | 1972-04-28 | 1974-01-09 | ||
JPH01238543A (en) * | 1988-03-16 | 1989-09-22 | Shiseido Co Ltd | Composition for oral cavity application |
JPH03133334A (en) * | 1989-10-19 | 1991-06-06 | Takara Nenryo Kogyo Kk | Antiseptic composition and antiseptic water containing the same |
JPH07238002A (en) * | 1994-02-28 | 1995-09-12 | Yakurigaku Chuo Kenkyusho:Kk | Nonvolatile earthworm control agent composed of high-concentration hinokitiol |
WO2004041229A1 (en) * | 2002-11-07 | 2004-05-21 | Nippon Zettoc Co.,Ltd. | Base for oral composition and oral composition |
-
2007
- 2007-06-27 JP JP2007169331A patent/JP5274792B2/en active Active
-
2008
- 2008-06-27 WO PCT/JP2008/061764 patent/WO2009001937A1/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS491718A (en) * | 1972-04-28 | 1974-01-09 | ||
JPH01238543A (en) * | 1988-03-16 | 1989-09-22 | Shiseido Co Ltd | Composition for oral cavity application |
JPH03133334A (en) * | 1989-10-19 | 1991-06-06 | Takara Nenryo Kogyo Kk | Antiseptic composition and antiseptic water containing the same |
JPH07238002A (en) * | 1994-02-28 | 1995-09-12 | Yakurigaku Chuo Kenkyusho:Kk | Nonvolatile earthworm control agent composed of high-concentration hinokitiol |
WO2004041229A1 (en) * | 2002-11-07 | 2004-05-21 | Nippon Zettoc Co.,Ltd. | Base for oral composition and oral composition |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019069927A (en) * | 2017-10-11 | 2019-05-09 | 小林製薬株式会社 | Oral composition |
JP7409759B2 (en) | 2017-10-11 | 2024-01-09 | 小林製薬株式会社 | Oral composition |
Also Published As
Publication number | Publication date |
---|---|
WO2009001937A1 (en) | 2008-12-31 |
JP5274792B2 (en) | 2013-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2997312C (en) | Oral care compositions comprising an amino acid, mixed zinc ion sources, and a cellulose/polysaccharide thickening system | |
JP4836227B2 (en) | Composition for preventing oral dryness and alleviating oral irritation | |
US20120020897A1 (en) | Dentifrice composition | |
KR20130063466A (en) | Dentifrice composition | |
JP2011140454A (en) | Composition for oral cavity | |
JP5924002B2 (en) | Dentifrice composition | |
JP6138538B2 (en) | Transparent liquid composition for oral cavity | |
JP6125859B2 (en) | Composition for external use | |
JP2019163238A (en) | Oral composition | |
WO2018066341A1 (en) | Oral composition and method for suppressing discoloration of formulation and liquid separation thereof | |
JP5620119B2 (en) | Non-diluted liquid oral composition and method of use | |
JP5274792B2 (en) | Hinokitiol-containing hydrophilic composition | |
JP7359909B2 (en) | A method for producing an oral composition, a method for improving the adhesion of an oral composition to an oral application part, and a method for improving retention of an oral composition in an oral application part. | |
JP5274793B2 (en) | Hinokitiol-containing hydrophilic composition | |
JP6409618B2 (en) | Dentifrice composition | |
JP5231778B2 (en) | Denture stabilizer | |
CN114867455B (en) | Oral composition | |
JP2019206486A (en) | Composition for oral cavity | |
JP5130601B2 (en) | Semi-solid oral composition | |
JP2002003354A (en) | Hinokitiol-containing composition for oral cavity | |
JPH11279038A (en) | Dentifrice composition | |
JP2007091737A (en) | Oral composition | |
JP2010208951A (en) | Oral composition | |
JP4052739B2 (en) | Dentifrice composition | |
WO2022145160A1 (en) | Composition for oral cavity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100506 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130306 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130430 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130515 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5274792 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |